HERMAN-MILLER
11.1.2023 14:31:39 CET | Business Wire | Press release
Herman Miller is continuing to increase the use of ocean-bound plastic within the modern furniture maker’s portfolio. The Sayl Chair, designed by esteemed Swiss Designer Yves Béhar will now include up to 1.36 kg (3 pounds) of mismanaged plastic waste found near waterways. This change builds upon the momentum created by the introduction of ocean-plastic in the iconic Aeron Chair in 2021 and will divert 95 metric tons*, the equivalent of approximately 9.6 million plastic water bottles, from the ocean annually.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005101/en/
Herman Miller Continues Expansion of Pioneering Use of Ocean-Bound Plastic With Updated Sayl Chair (Photo: Business Wire)
As part of the MillerKnoll collective, today’s announcement highlights Herman Miller’s ongoing commitment to sustainability, and long-term goal to increase recycled content to at least 50 percent, including the use of ocean-bound plastic, across all material the Company uses by 2030.
Sayl joins an impressive roster of Herman Miller products now being made with ocean-bound plastic. Between Aeron, Sayl, and other product lines including OE1 and Revenio textiles, the Company estimates that 234 metric tons of ocean-bound plastic, the equivalent of 23 million water bottles, will be diverted from the ocean annually.
“True innovation isn’t always about making new products,” says Gabe Wing, Director of Sustainability at MillerKnoll. “Oftentimes it can be looking for ways to use new research, perspectives, and resources to improve what already exists. Our team is incredibly excited to continue to improve and introduce products that promote responsible use of Earth’s resources.”
Since its introduction in 2010, the Sayl chair has been a leader in responsible design. Inspired by the Golden Gate Bridge, the eco-dematerialized design of Sayl was specifically created to use less material in inventive ways while providing ergonomic support and comfort. Additionally, the chair is 92% recyclable at the end of life.
Yves Béhar, the designer of Sayl and founder of fuseproject, commented on the announcement: “Charles Eames once said ‘Design is never done.’ That is true for the Sayl chair as improvements continue to be made years and years after launch. It was designed from the start as a light, simple, and lower carbon footprint chair in the full-featured task chairs category. And now, years after its launch I’m excited to see Sayl manufactured in recycled plastic diverted from rivers and oceans as the next step in bettering the design. At fuseproject, that has always been a focus and passion, and will continue to be central to our work.”
All colours of the Sayl chair will include ocean-bound plastic, which will grow to include the special edition versions created for Herman Miller Gaming in the future. Depending on the color chosen, each Sayl will have between .907kg (2 pounds) and 1.36kg (3 pounds) of ocean-bound plastic incorporated, with the Black version of Sayl having the highest. Sayl with ocean-bound plastic is available in Europe now and will be available in other areas of the globe later in 2023.
Herman Miller also announced that all colours of the Aeron are now available with ocean-bound plastic starting in November. The Onyx, Graphite, Mineral, and Carbon colours contain up to 1.13 kg (2.5 pounds) of ocean-bound plastic per chair.
To learn more about the specific environmental information for each variation of the Sayl or Aeron Chairs and to see how purchasing these items can contribute to green building standards including LEED, please visit https://millerknoll.ecomedes.com/.
About Herman Miller
Since 1905, Herman Miller has been guided by a commitment to problem-solving designs that inspire the best in people. Along the way, Herman Miller has forged critical relationships with the most visionary designers of the day, from midcentury greats like George Nelson, the Eames Office, and Isamu Noguchi, to research-oriented visionaries like Robert Propst and Bill Stumpf — and with today’s groundbreaking studios like Industrial Facility and Studio 7.5. From the birth of ergonomic furniture to manufacturing some of the twentieth century’s most iconic pieces, Herman Miller has spent the last century pioneering original, timeless design that makes an enduring impact, while building a lasting legacy of design, innovation and social good. Herman Miller is a part of MillerKnoll, a collective of dynamic brands that comes together to design the world we live in.
*Based on current selling forecasts.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
